Ligne de temps
Jeanne Chiaravalli
Ingénieur(e) de Recherche
01 août 2025
publication
Design, synthesis, biophysical and biological evaluation of original condensed pyrrolopyrimidine and pyrrolopyridine ligands as anti-SARS-CoV-2 agents targeting G4
Lire plus02 mai 2025
26 févr. 2025
02 déc. 2024
publication
High Content Screening Assay of Inhibitors of the Legionella Pneumophila Histone Methyltransferase RomA in Infected Cells.
Lire plus21 juin 2024
publication
High-throughput screening identifies broad-spectrum Coronavirus entry inhibitors.
Lire plus15 janv. 2024
21 avr. 2023
publication
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
Lire plus22 mars 2023
04 juil. 2022
publication
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Lire plus17 juin 2022
news
New publication – Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
Lire plus01 mai 2022
publication
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
Lire plus21 sept. 2021
publication
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.
Lire plus01 sept. 2021
publication
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Lire plus25 mai 2021
publication
Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues.
Lire plus05 juin 2015